Three years after its first investment, Roche AG (SIX: RO) bought the rest of Foundation Medicine, Inc., a Cambridge, Massachusetts-based molecular information company. In January 2015, Roche plunked down $1.03 billion to acquire approximately 57% of Foundation Medicine from its venture capital backers Google Ventures, Third Rock Ventures and Kleiner, Perkins, Caufield & Byers. Roche […]
Roche (SIX: RO) couldn’t let a good startup slip away. The Swiss drug maker announced it will pay $1.9 billion to keep New York City-based Flatiron Health, Inc. from going public. When it was founded in 2012, Flatiron’s goal was to gather and analyze data on cancer treatments and sells software based on those insights […]
Johnson & Johnson swallowed hard and upped its bid for Swiss biotech Actelion, winning the deal with a $30.2 billion bid.
The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is […]
Last year, the Laboratory, MRI & Dialysis sector posted robust deal volume, relatively speaking. The total of 52 announced transactions was a 58% gain compared with the year before, and better than every year since 2007, when 54 deals were announced (see the chart below). Two of the deals targeting a diagnostic lab or technology were made […]
Halfway through the month of January 2016, 12 pharmaceutical deals have been announced, with a total of $32.8 billion. You might think that’s a result of the annual JP Morgan Healthcare Summit that’s held every year in the second week of January. That’s only half right. Last year, only nine pharma deals were announced the […]